ATE181830T1 - Angiotensin-ii-antagonisten gegen erkrankungen; die mit einer eingeschränkten; neuronalen leitungsgeschwindigkeit verbunden sind, insbesondere diabetische neuropathie - Google Patents

Angiotensin-ii-antagonisten gegen erkrankungen; die mit einer eingeschränkten; neuronalen leitungsgeschwindigkeit verbunden sind, insbesondere diabetische neuropathie

Info

Publication number
ATE181830T1
ATE181830T1 AT93909041T AT93909041T ATE181830T1 AT E181830 T1 ATE181830 T1 AT E181830T1 AT 93909041 T AT93909041 T AT 93909041T AT 93909041 T AT93909041 T AT 93909041T AT E181830 T1 ATE181830 T1 AT E181830T1
Authority
AT
Austria
Prior art keywords
angiotensin
conduction velocity
diabetic neuropathy
restricted
those
Prior art date
Application number
AT93909041T
Other languages
English (en)
Inventor
Frank Carey
Alexander Anthony Oldham
Norman Eugene Cameron
Mary Anne Cotter
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929208116A external-priority patent/GB9208116D0/en
Priority claimed from GB929211289A external-priority patent/GB9211289D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of ATE181830T1 publication Critical patent/ATE181830T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT93909041T 1992-04-13 1993-04-07 Angiotensin-ii-antagonisten gegen erkrankungen; die mit einer eingeschränkten; neuronalen leitungsgeschwindigkeit verbunden sind, insbesondere diabetische neuropathie ATE181830T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929208116A GB9208116D0 (en) 1992-04-13 1992-04-13 Therapeutic agents
GB929211289A GB9211289D0 (en) 1992-05-28 1992-05-28 Heterocyclic therapeutic agents

Publications (1)

Publication Number Publication Date
ATE181830T1 true ATE181830T1 (de) 1999-07-15

Family

ID=26300705

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93909041T ATE181830T1 (de) 1992-04-13 1993-04-07 Angiotensin-ii-antagonisten gegen erkrankungen; die mit einer eingeschränkten; neuronalen leitungsgeschwindigkeit verbunden sind, insbesondere diabetische neuropathie

Country Status (14)

Country Link
EP (2) EP0636027B1 (de)
JP (1) JPH07505646A (de)
KR (1) KR100292396B1 (de)
AT (1) ATE181830T1 (de)
AU (1) AU675935B2 (de)
CA (1) CA2132544C (de)
DE (1) DE69325574T2 (de)
DK (1) DK0636027T3 (de)
ES (1) ES2135472T3 (de)
GR (1) GR3031261T3 (de)
HU (1) HUT71331A (de)
NO (1) NO313935B1 (de)
NZ (1) NZ251741A (de)
WO (1) WO1993020816A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11513395A (ja) * 1995-10-06 1999-11-16 ノバルティス・アクチエンゲゼルシャフト 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのａｔ１−レセプターアンタゴニスト
ATE230263T1 (de) 1996-02-29 2003-01-15 Novartis Erfind Verwalt Gmbh At1 rezeptor antagonist zur anregung von apoptosis
NZ330774A (en) * 1996-04-05 1999-06-29 Takeda Chemical Industries Ltd Pharmaceutical composition having angiotensin ii antagonistic activity or salt thereof with an insulin-sensitivity increasing compound and postprandial hyperglycemia in diabetes mellitus and antagonistic activity and increased insulin-sensitivity
US6465502B1 (en) 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
NZ511938A (en) 1998-12-23 2004-02-27 Novartis Ag Use of AT-1 receptor antagonist or treating diseases associated with an increase of AT-1 receptor
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
NZ555334A (en) 2004-12-24 2010-05-28 Spinifex Pharm Pty Ltd Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist
US20130131007A1 (en) 2005-09-07 2013-05-23 Bebaas, Inc. Vitamin b12 compositions
JP5230595B2 (ja) 2006-03-20 2013-07-10 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド 炎症性疼痛の治療または予防の方法
EP1908469A1 (de) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II Rezeptor Antagonisten zur Behandlung von systemischen Krankheiten bei Katzen
ES2560327T3 (es) * 2010-01-19 2016-02-18 Novartis Ag Métodos y composiciones para una velocidad de conducción nerviosa mejorada
NZ759782A (en) 2017-07-07 2023-06-30 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats
EP3996709A1 (de) 2019-07-09 2022-05-18 Boehringer Ingelheim Vetmedica GmbH Telmisartan zur behandlung von bluthochdruck bei hunden
CN121175053A (zh) 2023-05-24 2025-12-19 勃林格殷格翰动物保健有限公司 包含一或多种sglt-2抑制剂及替米沙坦的非人类哺乳动物中肾脏疾病和/或高血压的组合治疗和/或预防
TW202541793A (zh) 2023-12-15 2025-11-01 德商百靈佳殷格翰維美迪加股份有限公司 用於預防貓之全身性疾病之血管緊張素ii受體拮抗劑

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE117294T1 (de) * 1989-08-11 1995-02-15 Ici Plc Chinolin-derivate, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel.
GB8927277D0 (en) * 1989-12-01 1990-01-31 Glaxo Group Ltd Chemical compounds
US5140037A (en) * 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists
US5049565A (en) * 1990-12-07 1991-09-17 Merck & Co., Inc. Microbial transformation process for preparing anti-hypertensive products
GB9027210D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027211D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
AU1625192A (en) * 1991-05-31 1992-12-03 Zeneca Limited Heterocyclic derivatives
DK0528762T3 (da) * 1991-08-15 1997-08-25 Ciba Geigy Ag N-acyl-N-heterocyclyl- eller naphthylalkyl-aminosyrer som angiotensin II antagonister

Also Published As

Publication number Publication date
JPH07505646A (ja) 1995-06-22
DE69325574T2 (de) 2000-03-16
ES2135472T3 (es) 1999-11-01
NZ251741A (en) 1997-06-24
NO943846L (no) 1994-10-12
HU9402932D0 (en) 1995-02-28
EP0636027B1 (de) 1999-07-07
GR3031261T3 (en) 1999-12-31
EP0636027A1 (de) 1995-02-01
AU3958993A (en) 1993-11-18
CA2132544A1 (en) 1993-10-28
DE69325574D1 (de) 1999-08-12
WO1993020816A1 (en) 1993-10-28
CA2132544C (en) 2005-10-18
EP0872235A1 (de) 1998-10-21
DK0636027T3 (da) 2000-01-31
HUT71331A (en) 1995-11-28
KR100292396B1 (de) 2001-09-17
AU675935B2 (en) 1997-02-27
NO313935B1 (no) 2002-12-30
NO943846D0 (no) 1994-10-12

Similar Documents

Publication Publication Date Title
DE69325574D1 (de) ANGIOTENSIN-II-ANTAGONISTEN GEGEN ERKRANKUNGEN; DIE MIT EINER EINGESCHRäNKTEN; NEURONALEN LEITUNGSGESCHWINDIGKEIT VERBUNDEN SIND, INSBESONDERE DIABETISCHE NEUROPATHIE
BR9101256A (pt) Composto,composicao fungicida,processo fungicida,composicao inseticida ou acaricida e processo inseticida ou acaricida
ES2058346T3 (es) Compuestos piperidinilicos 1,4-disustituidos.
ES2081939T3 (es) Glutarimidas.
BR9814040A (pt) Agudo no pulmão com fibrose com antagonistas de avb6
ES2164684T3 (es) Uso de antagonistas de taquiquininas en el tratamiento de emesis.
DE69407596D1 (de) Wässrige dispersionen, die cyclopolymere als dispergiermittel enthalten
EP0998918A3 (de) Feste Dosierungsform mit copolymerem Bindemittel
FR2718349B1 (fr) Compositions cosmétiques à appliquer sur l'ongle.
FR2727625B1 (fr) Composition translucide applicable sur l'ongle
IT1269185B (it) Associazione dotata di effetto sinergico che ha un effetto antagonista dei recettori nk1 e nk2
BR9900608A (pt) Agente antimicrobianos, composições de resinas antimicrobianas, e, artigos tendo atividade antimicrobiana
BR9101255A (pt) Composto,composicao e processo fungicida,composicao e processo inseticida ou acaricida
NO891627L (no) Vandige dispersjoner med synergistiske dispergeringskombinasjoner.
NO890229L (no) Metallekstraksjonsprosess.
DE3580227D1 (de) Leukotrien-antagonisten, ihre herstellung und verwendung und pharmazeutische zusammensetzungen, die sie enthalten, und deren herstellung.
DE69021297D1 (de) Verschlussvorrichtung, welche auch als Blendeneinrichtung nutzbar ist.
ES2135535T3 (es) Derivados tiazolotriazol y tiazolodiazol con actividad fungicida.
ES2056876T3 (es) Compuestos piperidinilicos 1,4-disustituidos.
FR2700692B1 (fr) Vernis à ongles, incolore ou coloré, contenant en association une amino- ou thiosilicone et un composé organofluoré hydrocarboné en vue d'améliorer le temps de séchage.
DE69019395D1 (de) Zusammensetzung gegen Mikroben.
Jolly The good-sense guide to avoiding disasters with seamless floors
Wilson Getting the workplace first aid requirements right
DE59201157D1 (de) Verwendung isomerer 1,1,1-trialkyl-2-phenyl-ethan-derivate als riechstoffe, sowie diese enthaltende riechstoffkompositionen.
ATE111691T1 (de) Mittel gegen ratten.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee